At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
TAK-935 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.
In Brief
A Phase 1 clinical trial evaluating TAK-935 and [18F]MNI-792 (tracer) for Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the brain cholesterol 24S-hydroxylase (CH24H) enzyme occupancy of TAK-935 after single oral dose in healthy participants using the positron emission tomography (PET) ligand \[18F\]MNI-792 and PET imaging and to determine the relationship of occupancy to TAK-935 exposure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedJul 2015
Primary CompletionDec 2015
Study CompletionJan 2016
TodayJul 2026
First PostedJul 14, 2015
Enrollment StartJul 1, 2015
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.0 years ago
Interventions
TAK-935drug
TAK-935 oral solution.
[18F]MNI-792 (tracer)drug
\[18F\]MNI-792 injection.